Compare BAX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAX | ABVX |
|---|---|---|
| Founded | 1931 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 9.6B |
| IPO Year | N/A | N/A |
| Metric | BAX | ABVX |
|---|---|---|
| Price | $19.61 | $117.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $25.67 | ★ $112.83 |
| AVG Volume (30 Days) | ★ 8.2M | 1.7M |
| Earning Date | 10-30-2025 | 08-11-2025 |
| Dividend Yield | ★ 0.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,023,000,000.00 | $7,073,400.00 |
| Revenue This Year | $5.20 | $6.80 |
| Revenue Next Year | $2.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.90 | N/A |
| 52 Week Low | $17.40 | $4.77 |
| 52 Week High | $37.74 | $138.49 |
| Indicator | BAX | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 53.15 |
| Support Level | $17.92 | $107.06 |
| Resistance Level | $19.17 | $138.49 |
| Average True Range (ATR) | 0.47 | 7.25 |
| MACD | 0.23 | -0.35 |
| Stochastic Oscillator | 89.47 | 37.95 |
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.